Search Result

Pathways Recommended:	Antibody-Drug Conjugate/ADC Related

Results for "

ADC control

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibodies (12) ADC Payloads (2) Antibody-Drug Conjugates (ADCs) (17) c-Met/HGFR (1) CD22 (1) CD3 (1) Drug Intermediate (2) Integrin (2) Interleukin Related (2) Isotope-Labeled Compounds (1) Microtubule/Tubulin (3) Nectin-4 (1) PSMA (1) ROR (2) Sodium Phosphate Cotransporter (1) Topoisomerase (2) Transmembrane Glycoprotein (2) TROP2 (1)
By Research Areas:	Cancer (35) Inflammation/Immunology (1)
Click Chemistry:	ADC Synthesis (1) Azide (1)

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Inhibitory Antibodies

Isotope-Labeled Compounds

Click Chemistry

Targets Recommended: ADC Payloads ADC Antibodies Drug-Linker Conjugates for ADC ADC Linkers

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-164153

ADC Control Human IgG1-vcMMAE (DAR4, solution)	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
ADC Control Human IgG1-vcMMAE (DAR4, solution) is a humanized monoclonal antibody that is an isotype control of *ADC* human IgG1-vcMMAE and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is vcMMAE (HY-15575) .

HY-164152A

ADC Control Human IgG1-Deruxtecan (DAR 8)	Antibody-Drug Conjugates (ADCs) Topoisomerase	Cancer
ADC Control Human IgG1-Deruxtecan (DAR 8) is a humanized monoclonal antibody that is an isotype control of *ADC* human IgG1-Deruxtecan and can inhibit DNA topoisomerase I. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E) .

HY-164152

ADC Control Human IgG1-Deruxtecan (DAR 4)	Antibody-Drug Conjugates (ADCs) Topoisomerase	Cancer
ADC Control Human IgG1-Deruxtecan (DAR 4) is a humanized monoclonal antibody that is an isotype control of *ADC* human IgG1-Deruxtecan and can inhibit DNA topoisomerase I. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E) .

HY-P99971

Gemtuzumab	ADC Antibodies Transmembrane Glycoprotein	Cancer
Gemtuzumab is a monoclonal IgG4-κ antibody targeting CD33 antigen. Gemtuzumab affects cell necrosis by specifically targeting CD33 expressed on the surface of leukaemic cell blasts in acute myeloid leukemia (AML). Gemtuzumab can be used for synthesis of antibody-drug conjugate (ADC), Gemtuzumab ozogamicin (HY-109539). Gemtuzumab ozogamicin consists of a cytotoxic derivative of Calicheamicin (a cytotoxic antibiotic), and a monoclonal antibody. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

HY-P991041

Turmetabart Anti-SEZ6 Antibody (SC17); ABBV-011 antibody; ABBV-706 antibody	ADC Antibodies	Cancer
Turmetabart (Anti-SEZ6 Antibody (SC17)) is a humanized anti-SEZ6 IgG1 monoclonal antibody. Anti-SEZ6 Antibody (SC17) can be used to synthesize antibody-drug conjugates (ADC) product, ABBV-011. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P990764

Sigvotatug SGN-B6A antibody	Integrin ADC Antibodies	Inflammation/Immunology Cancer
Sigvotatug (SGN-B6A antibody) is a human IgG1 κ monoclonal antibody against ITGB6. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001). Sigvotatug can be used as an ADC antibody to synthesize ADC Sigvotatug vedotin (HY-164957) .

HY-145626

Ozuriftamab 1 Publications Verification BA302	ADC Antibodies ROR	Cancer
Ozuriftamab is a human IgG1 kappa antibody of ROR2. Ozuriftamab can be used to synthesize ADC such as Ozuriftamab vedotin (HY-145627). Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P991204

Anti-PSMA Antibody ARX517 antibody	PSMA	Cancer
Anti-PSMA Antibody (ARX517 antibody) is a humanized IgG1 monoclonal antibody that targets PSMA. Anti-PSMA Antibody is the antibody part of the ADC molecule ARX517. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-164668

ADC Control Human IgG1-SN-38	Antibody-Drug Conjugates (ADCs)	Cancer
ADC Control Human IgG1-SN-38 is an isotype control of ADC Human IgG1-SN-38. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is CL2A-SN-38 (HY-128946).

HY-164154

ADC Control Human IgG1-vcMMAF	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
ADC Control Human IgG1-vcMMAF is a humanized monoclonal antibody that is an isotype control of *ADC* human IgG1-vcMMAF and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is MC-Val-Cit-PAB-MMAF (vcMMAF; HY-112786) .

HY-P99229

Upifitamab 2 Publications Verification XMT-1535; Upinitatug	ADC Antibodies	Cancer
Upifitamab is a humanized monoclonal antibody targeting NaPi2b. Upifitamab can be used to synthesize ADC such as Upfitamab rilsodotin. Upfitamab rilsodotin can be used in research for solid tumors including high-grade serious epithelial ovarian, fallopian tube and primary peritoneal cancer (OC). Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-145149

Duostatin 5	ADC Payloads	Cancer
Duostatin 5 is a ADC Cytotoxin designed based on MMAF (HY-15579) and can be used to synthesize *ADCs. The preparation of Duostatin 5 has the advantages of fewer synthetic steps, simple operation, less difficulty in quality control*, and more stable chemical synthesis process. Duostatin 5 can be linked to the antibody targeting 5T4 (ZV05) by cross-linking with interchain cysteines through a disubstituted C-Lock linker. Duostatin 5 is a click chemistry reagent. It contains an azide group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing alkyne groups. It can also undergo ring strain-driven alkyne-azide cycloaddition (SPAAC) with molecules containing DBCO or BCN groups[1][2].

HY-P99970

Lifastuzumab	ADC Antibodies Sodium Phosphate Cotransporter	Cancer
Lifastuzumab is a humanized anti-NaPi2b IgG1 monoclonal antibody. Lifastuzumab can be coupled with monomethyl auristatin E (MMAE) (HY-15162) through ADC Linker to form an antibody-drug conjugate (ADC) Lifastuzumab vedotin (HY-P99705) with anticancer activity. Lifastuzumab vedotin can be studied in research for non-small cell lung cancer and ovarian cancer. Recommend Isotype Control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P99233

Camidanlumab HuMax-TAC	ADC Antibodies Transmembrane Glycoprotein Interleukin Related	Cancer
Camidanlumab (HuMax-TAC) is a humanized IgG1 monoclonal antibody against CD25. Camidanlumab can be used to synthesize the ADC molecule Camidanlumab tesirine (HY-141599). Camidanlumab can be used in the research of tumors such as lymphoma and leukemia. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P99230

Pinatuzumab	Integrin CD22	Cancer
Pinatuzumab is a humanized monoclonal antibody targeting cell-surface antigen CD22. Pinatuzumab can be used to synthesize antibody-drug conjugate (ADC) such as Pinatuzumab vedotin (HY-141602). Pinatuzumab can be studied in research on cancer such as non-Hodgkin lymphoma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P991197

Anti-GPRC5D Antibody LM-305 antibody; AZD-0305 antibody	CD3	Cancer
Anti-GPRC5D Antibody (LM-305 antibody) is a humanized IgG1 monoclonal antibody that targets GPRC5D. Anti-GPRC5D Antibody is the antibody part of the ADC molecule LM-305. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P991699

Lixarkitug AZD9829 antibody; INT-020	ADC Antibodies Interleukin Related	Cancer
Lixarkitug (AZD9829 antibody; INT-020) is a humanized IgG1κ antibody targeting IL-3Ra/CD123. Lixarkitug can be conjugated with Samrotecan to form the intact *ADC* molecule lixarkitug samrotecan (AZD9829), which is used in studies of acute myeloid leukemia (AML) . The isotype control corresponding to Lixarkitug is Human IgG1 kappa, Isotype Control (HY-P99001).

HY-164669

ADC Control Human IgG1-DM4	Antibody-Drug Conjugates (ADCs)	Cancer
ADC Control Human IgG1-DM4 is an isotype control of ADC Human IgG1-DM4. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is SPDB-DM4 (HY-12460).

HY-150362

ADC Control Human IgG1-tirumotecan	Antibody-Drug Conjugates (ADCs)	Cancer
ADC Control Human IgG1-tirumotecan is an antibody-drug conjugate (ADC). The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is TL033 TFA (HY-147340A). ADC Control Human IgG1-tirumotecan can be as a control of Sacituzumab tirumotecan (HY-164789).

HY-164954

ADC Control Human IgG1-McMMAF	Antibody-Drug Conjugates (ADCs)	Cancer
ADC Control Human IgG1-McMMAF is an antibody-drug conjugate (ADC) composed of the ADC antibody IgG1 Human IgG1 kappa, Isotype Control (HY-P99001) and the payload McMMAF (HY-15578).

HY-159774

ADC Control human IgG1-DM1	Antibody-Drug Conjugates (ADCs)	Cancer
ADC Control human IgG1-DM1 is the ADC control, which is composed of Human IgG1 kappa, Isotype Control (HY-P99001) and the linker-payload conjugate SMCC-DM1 (HY-101070) .

HY-150363

ADC Control Human IgG1-sulfo-SPDB-DM4	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
ADC Control Human IgG1-sulfo-SPDB-DM4 is an antibody-drug conjugate (ADC) and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is sulfo-SPDB-DM4 (HY-101141) .

HY-78931A

(R,S,S,R,S)-Boc-Dap-NE	Drug Intermediate	Cancer
(R,S,S,R,S)-Boc-Dap-NE is the inactive isomer of Boc-Dap-NE (HY-78931), and can be used as an experimental control. Boc-Dap-NE, is an intermediate in the synthesis of Monomethyl auristatin E (HY-15162), which is an inhibitor of tubulin polymerization. Monomethyl auristatin E can be used to synthesize Antibody-Drug Conjugates (ADCs) as ADC Cytotoxin.

HY-P991640

Anti-TDGF1 antibody (huB3F6) BIIB015 antibody	ADC Antibodies	Cancer
Anti-TDGF1 antibody (huB3F6) (BIIB015 antibody) is a CHO-expressed human antibody that targets TDGF1. Anti-TDGF1 antibody has huIgG1 heavy chain and huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-TDGF1 antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001). Anti-TDGF1 antibody (huB3F6) can be used for synthesis of *ADCs* .

HY-185794

ADC Control Human IgG1 drozuntecan (DAR 6)	Antibody-Drug Conjugates (ADCs)	Cancer
ADC Control Human IgG1 drozuntecan (DAR 6) is an antibody-drug conjugate control with a drug-to-antibody ratio of 6 .

HY-65039A

rel-Boc-Hyp-OMe	Others	Cancer
rel-Boc-Hyp-OMe is the isomer of Boc-Hyp-OMe (HY-65039), and can be used as an experimental control. Boc-Hyp-OMe is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Boc-Hyp-OMe is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs .

HY-78931B

(S,S,S,S,R)-Boc-Dap-NE	Drug Intermediate	Cancer
(S,S,S,S,R)-Boc-Dap-NE is the inactive isomer of Boc-Dap-NE (HY-78931), and can be used as an experimental control. Boc-Dap-NE, is an intermediate in the synthesis of Monomethyl auristatin E (HY-15162), which is an inhibitor of tubulin polymerization. Monomethyl auristatin E can be used to synthesize Antibody-Drug Conjugates (ADCs) as ADC Cytotoxin.

HY-185761

ADC Control Human IgG1-rezetecan	Antibody-Drug Conjugates (ADCs)	Others
ADC Control Human IgG1-rezetecan is an isotype-matched control antibody-drug conjugate (ADC) for Mocertatug rezetecan (HY-185280). Mocertatug rezetecan is an ADC targeting B7-H4 .

HY-185294

ADC Control Human IgG1-ED04	Antibody-Drug Conjugates (ADCs)	Others
ADC Control human IgG1-ED04 is an *ADC* control composed of Human IgG1 kappa, Isotype Control (HY-P99001) and ADC toxin ED04 (HY-153891). It can be used as an isotype control for BL-B01D1 (HY-164702).

HY-185188

ADC Control Human IgG1-DL-01	Antibody-Drug Conjugates (ADCs)	Others
ADC Control Human IgG1-DL-01 is an antibody-drug conjugate (ADC) consisting of the ADC antibody Human IgG1 lambda1, Isotype Control (HY-P99992) and the linker-payload DL-01 formic (HY-155870A).

HY-185774A

ADC Control Human IgG1(D356E/L358M)-LNK4 (DAR4)	Antibody-Drug Conjugates (ADCs)	Cancer
ADC Control Human IgG1 (D356E/L358M)-LNK4 (DAR4) is a control antibody-drug conjugate (ADC) with a drug-to-antibody ratio (DAR) of 4, formed by the conjugation of Human IgG1 (D356E/L358M) kappa, Isotype Control (HY-P990100) and LNK4-S (HY-170400). ADC Control Human IgG1 (D356E/L358M)-LNK4 (DAR4) serves as the isotype control for Farletuzumab-LNK4-S (DAR4) (HY-185773A) .

HY-185774

ADC Control Human IgG1(D356E/L358M)-LNK4 (DAR8)	Antibody-Drug Conjugates (ADCs)	Cancer
ADC Control Human IgG1 (D356E/L358M)-LNK4 (DAR8) is a control *ADC* with a drug-to-antibody ratio (DAR) of 8, consisting of Human IgG1 (D356E/L358M) kappa, Isotype Control (HY-P990100), which does not specifically bind to FRα, and LNK4-S (HY-170400). ADC Control Human IgG1 (D356E/L358M)-LNK4 (DAR8) serves as the isotype control for Farletuzumab-LNK4-S (DAR8) (HY-185773) .

HY-185775

ADC Control Human IgG1 (C214S light chain, C226V and C229V heavy chain)-Tesirine	Antibody-Drug Conjugates (ADCs)	Cancer
ADC Control Human IgG1 (C214S light chain, C226V and C229V heavy chain)-Tesirine is an isotype control antibody-drug conjugate for MEDI3726 (HY-185729). It carries hinge mutations including C214S in the light chain and C226V/C229V in the heavy chain, and the toxic molecule-linker conjugate is Tesirine (HY-128952). ADC Control Human IgG1 (C214S light chain, C226V and C229V heavy chain)-Tesirine can be used in the research of prostate cancer and metastatic castration-resistant prostate cancer .

HY-P992127

Renditatug BAT8008 Antibody; BAT0806	TROP2 ADC Antibodies	Cancer
Renditatug (BAT8008 Antibody) is an antibody targeting TROP2. Renditatug can be used for the synthesis of ADC BAT8008. The corresponding isotype control is: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P992133

Sutantatug SYS6002 Antibody; CRB-701 Antibody	ADC Antibodies Nectin-4	Cancer
Sutantatug (SYS6002 Antibody) is a monoclonal antibody targeting Nectin-4, and serves as the antibody moiety of the ADC CRB-701. Sutantatug is applicable to the research of Nectin-4-positive solid tumors, urothelial carcinoma and cervical cancer. The corresponding isotype control for Sutantatug is Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P992337

CS5001 Antibody	ROR	Cancer
CS5001 Antibody is an IgG1 human monoclonal antibody targeting ROR1. CS5001 Antibody can be used for the synthesis of the ADC CS5001. It is applicable to research related to advanced solid tumors and lymphomas. The recommended isotype control is human IgG1 kappa (HY-P99001) .

HY-145149S

Duostatin 5-13C,d3	Isotope-Labeled Compounds ADC Payloads	Cancer
Duostatin 5- ¹³C,d₃ is the ¹³C-labeled Duostatin 5 (HY-145149). Duostatin 5 is a ADC Cytotoxin designed based on MMAF (HY-15579) and can be used to synthesize *ADCs. The preparation of Duostatin 5 has the advantages of fewer synthetic steps, simple operation, less difficulty in quality control*, and more stable chemical synthesis process. Duostatin 5 can be linked to the antibody targeting 5T4 (ZV05) by cross-linking with interchain cysteines through a disubstituted C-Lock linker. Duostatin 5 is a click chemistry reagent. It contains an azide group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing alkyne groups. It can also undergo ring strain-driven alkyne-azide cycloaddition (SPAAC) with molecules containing DBCO or BCN groups[1][2].

HY-P992146

Zevontabart MYTX-011 Antibody; Q-397	ADC Antibodies c-Met/HGFR	Cancer
Zevontabart (MYTX-011 Antibody; Q-397) is a pH-dependent anti-c-MET antibody. Zevontabart regulates the trafficking process of c-MET to reduce receptor recycling, and enhances its own endocytosis and accumulation in c-MET-expressing cells. Zevontabart induces cytotoxicity in solid tumor cells and exerts anti-tumor activity in a non-small cell lung cancer xenograft mouse model. Zevontabart can be used to synthesize *ADC, such as: MYTX-011. Zevontabart can be used in studies related to non-small cell lung cancer, with its corresponding isotype control* being Human IgG1 kappa, Isotype Control (HY-P99001) .

Cat. No.	Product Name

HY-L256

Azide Compound Library	39 compounds
In modern drug discovery and chemical biology research, the azide group (-N₃) is an important functional moiety that is widely used in click chemistry, biomolecular labeling, drug delivery systems, and prodrug design due to its unique reactivity and bioorthogonality. The MCE Azide Structural Compound Library contains 39 compounds featuring -N₃ functional groups. It is designed for the construction of click chemistry reaction systems and the subsequent development of functional molecules. This library enables the rapid assembly of targeting ligands, linkers, and functional molecular modules, thereby accelerating PROTAC assembly, optimization of antibody-drug conjugate (ADC) linkers, and the development of biological labeling probes. In addition, the high reaction selectivity and excellent biocompatibility of the azide group allow it to maintain stable reactivity even in complex biological environments, improving controllability and efficiency in drug design. It serves as an indispensable molecular tool in modern medicinal chemistry and chemical biology research.

Azide Compound Library

39 compounds

In modern drug discovery and chemical biology research, the azide group (-N₃) is an important functional moiety that is widely used in click chemistry, biomolecular labeling, drug delivery systems, and prodrug design due to its unique reactivity and bioorthogonality.

The MCE Azide Structural Compound Library contains 39 compounds featuring -N₃ functional groups. It is designed for the construction of click chemistry reaction systems and the subsequent development of functional molecules. This library enables the rapid assembly of targeting ligands, linkers, and functional molecular modules, thereby accelerating PROTAC assembly, optimization of antibody-drug conjugate (ADC) linkers, and the development of biological labeling probes. In addition, the high reaction selectivity and excellent biocompatibility of the azide group allow it to maintain stable reactivity even in complex biological environments, improving controllability and efficiency in drug design. It serves as an indispensable molecular tool in modern medicinal chemistry and chemical biology research.

HY-L258

Alkyne Compound Library	384 compounds
In modern medicinal chemistry and chemical biology research, alkyne (-C≡C-) structures play an important role in click chemistry, bioorthogonal labeling, and the construction of functional molecules due to their unique linear geometry and high reactivity. In particular, driven by the development of copper-catalyzed azide-alkyne cycloaddition (CuAAC) and copper-free click reactions (SPAAC), terminal alkyne groups have become important “chemical handles” for building complex biomolecular systems. The MCE Alkyne Compound Library contains 384 compounds designed for the construction of click chemistry reaction systems and the development of diverse functional molecules. In drug discovery, these structures serve as key reactive sites that can efficiently undergo click reactions with azide groups, enabling modular assembly of PROTAC molecules, construction of ADC linkers, and rapid synthesis of bioorthogonal labeling probes. In addition, alkyne groups exhibit high stability, mild reaction conditions, and excellent biocompatibility, allowing them to maintain reactivity in complex biological environments. This contributes to improved efficiency and controllability in drug development, making them indispensable chemical building blocks in modern drug design and functional molecular engineering.

Alkyne Compound Library

384 compounds

In modern medicinal chemistry and chemical biology research, alkyne (-C≡C-) structures play an important role in click chemistry, bioorthogonal labeling, and the construction of functional molecules due to their unique linear geometry and high reactivity. In particular, driven by the development of copper-catalyzed azide-alkyne cycloaddition (CuAAC) and copper-free click reactions (SPAAC), terminal alkyne groups have become important “chemical handles” for building complex biomolecular systems.

The MCE Alkyne Compound Library contains 384 compounds designed for the construction of click chemistry reaction systems and the development of diverse functional molecules. In drug discovery, these structures serve as key reactive sites that can efficiently undergo click reactions with azide groups, enabling modular assembly of PROTAC molecules, construction of ADC linkers, and rapid synthesis of bioorthogonal labeling probes. In addition, alkyne groups exhibit high stability, mild reaction conditions, and excellent biocompatibility, allowing them to maintain reactivity in complex biological environments. This contributes to improved efficiency and controllability in drug development, making them indispensable chemical building blocks in modern drug design and functional molecular engineering.

Cat. No.	Product Name	Type

HY-164153

ADC Control Human IgG1-vcMMAE (DAR4, solution)	Fluorescent Dyes
ADC Control Human IgG1-vcMMAE (DAR4, solution) is a humanized monoclonal antibody that is an isotype control of *ADC* human IgG1-vcMMAE and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is vcMMAE (HY-15575) .

HY-164152A

ADC Control Human IgG1-Deruxtecan (DAR 8)	Fluorescent Dyes
ADC Control Human IgG1-Deruxtecan (DAR 8) is a humanized monoclonal antibody that is an isotype control of *ADC* human IgG1-Deruxtecan and can inhibit DNA topoisomerase I. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E) .

HY-164152

ADC Control Human IgG1-Deruxtecan (DAR 4)	Fluorescent Dyes
ADC Control Human IgG1-Deruxtecan (DAR 4) is a humanized monoclonal antibody that is an isotype control of *ADC* human IgG1-Deruxtecan and can inhibit DNA topoisomerase I. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E) .

HY-164154

ADC Control Human IgG1-vcMMAF	Fluorescent Dyes
ADC Control Human IgG1-vcMMAF is a humanized monoclonal antibody that is an isotype control of *ADC* human IgG1-vcMMAF and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is MC-Val-Cit-PAB-MMAF (vcMMAF; HY-112786) .

Cat. No.	Product Name	Target	Research Area	Image

HY-164153

ADC Control Human IgG1-vcMMAE (DAR4, solution)	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
ADC Control Human IgG1-vcMMAE (DAR4, solution) is a humanized monoclonal antibody that is an isotype control of *ADC* human IgG1-vcMMAE and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is vcMMAE (HY-15575) .

HY-164152

ADC Control Human IgG1-Deruxtecan (DAR 4)	Antibody-Drug Conjugates (ADCs) Topoisomerase	Cancer
ADC Control Human IgG1-Deruxtecan (DAR 4) is a humanized monoclonal antibody that is an isotype control of *ADC* human IgG1-Deruxtecan and can inhibit DNA topoisomerase I. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E) .

HY-P99971

Gemtuzumab	ADC Antibodies Transmembrane Glycoprotein	Cancer
Gemtuzumab is a monoclonal IgG4-κ antibody targeting CD33 antigen. Gemtuzumab affects cell necrosis by specifically targeting CD33 expressed on the surface of leukaemic cell blasts in acute myeloid leukemia (AML). Gemtuzumab can be used for synthesis of antibody-drug conjugate (ADC), Gemtuzumab ozogamicin (HY-109539). Gemtuzumab ozogamicin consists of a cytotoxic derivative of Calicheamicin (a cytotoxic antibiotic), and a monoclonal antibody. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

HY-P991041

Turmetabart Anti-SEZ6 Antibody (SC17); ABBV-011 antibody; ABBV-706 antibody	ADC Antibodies	Cancer
Turmetabart (Anti-SEZ6 Antibody (SC17)) is a humanized anti-SEZ6 IgG1 monoclonal antibody. Anti-SEZ6 Antibody (SC17) can be used to synthesize antibody-drug conjugates (ADC) product, ABBV-011. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P990764

Sigvotatug SGN-B6A antibody	Integrin ADC Antibodies	Inflammation/Immunology Cancer
Sigvotatug (SGN-B6A antibody) is a human IgG1 κ monoclonal antibody against ITGB6. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001). Sigvotatug can be used as an ADC antibody to synthesize ADC Sigvotatug vedotin (HY-164957) .

HY-145626

Ozuriftamab 1 Publications Verification BA302	ADC Antibodies ROR	Cancer
Ozuriftamab is a human IgG1 kappa antibody of ROR2. Ozuriftamab can be used to synthesize ADC such as Ozuriftamab vedotin (HY-145627). Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P991204

Anti-PSMA Antibody ARX517 antibody	PSMA	Cancer
Anti-PSMA Antibody (ARX517 antibody) is a humanized IgG1 monoclonal antibody that targets PSMA. Anti-PSMA Antibody is the antibody part of the ADC molecule ARX517. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-164154

ADC Control Human IgG1-vcMMAF	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
ADC Control Human IgG1-vcMMAF is a humanized monoclonal antibody that is an isotype control of *ADC* human IgG1-vcMMAF and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is MC-Val-Cit-PAB-MMAF (vcMMAF; HY-112786) .

HY-P99229

Upifitamab 2 Publications Verification XMT-1535; Upinitatug	ADC Antibodies	Cancer
Upifitamab is a humanized monoclonal antibody targeting NaPi2b. Upifitamab can be used to synthesize ADC such as Upfitamab rilsodotin. Upfitamab rilsodotin can be used in research for solid tumors including high-grade serious epithelial ovarian, fallopian tube and primary peritoneal cancer (OC). Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P99970

Lifastuzumab	ADC Antibodies Sodium Phosphate Cotransporter	Cancer
Lifastuzumab is a humanized anti-NaPi2b IgG1 monoclonal antibody. Lifastuzumab can be coupled with monomethyl auristatin E (MMAE) (HY-15162) through ADC Linker to form an antibody-drug conjugate (ADC) Lifastuzumab vedotin (HY-P99705) with anticancer activity. Lifastuzumab vedotin can be studied in research for non-small cell lung cancer and ovarian cancer. Recommend Isotype Control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P99233

Camidanlumab HuMax-TAC	ADC Antibodies Transmembrane Glycoprotein Interleukin Related	Cancer
Camidanlumab (HuMax-TAC) is a humanized IgG1 monoclonal antibody against CD25. Camidanlumab can be used to synthesize the ADC molecule Camidanlumab tesirine (HY-141599). Camidanlumab can be used in the research of tumors such as lymphoma and leukemia. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P99230

Pinatuzumab	Integrin CD22	Cancer
Pinatuzumab is a humanized monoclonal antibody targeting cell-surface antigen CD22. Pinatuzumab can be used to synthesize antibody-drug conjugate (ADC) such as Pinatuzumab vedotin (HY-141602). Pinatuzumab can be studied in research on cancer such as non-Hodgkin lymphoma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P991197

Anti-GPRC5D Antibody LM-305 antibody; AZD-0305 antibody	CD3	Cancer
Anti-GPRC5D Antibody (LM-305 antibody) is a humanized IgG1 monoclonal antibody that targets GPRC5D. Anti-GPRC5D Antibody is the antibody part of the ADC molecule LM-305. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P991699

Lixarkitug AZD9829 antibody; INT-020	ADC Antibodies Interleukin Related	Cancer
Lixarkitug (AZD9829 antibody; INT-020) is a humanized IgG1κ antibody targeting IL-3Ra/CD123. Lixarkitug can be conjugated with Samrotecan to form the intact *ADC* molecule lixarkitug samrotecan (AZD9829), which is used in studies of acute myeloid leukemia (AML) . The isotype control corresponding to Lixarkitug is Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P991640

Anti-TDGF1 antibody (huB3F6) BIIB015 antibody	ADC Antibodies	Cancer
Anti-TDGF1 antibody (huB3F6) (BIIB015 antibody) is a CHO-expressed human antibody that targets TDGF1. Anti-TDGF1 antibody has huIgG1 heavy chain and huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-TDGF1 antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001). Anti-TDGF1 antibody (huB3F6) can be used for synthesis of *ADCs* .

HY-P992127

Renditatug BAT8008 Antibody; BAT0806	TROP2 ADC Antibodies	Cancer
Renditatug (BAT8008 Antibody) is an antibody targeting TROP2. Renditatug can be used for the synthesis of ADC BAT8008. The corresponding isotype control is: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P992133

Sutantatug SYS6002 Antibody; CRB-701 Antibody	ADC Antibodies Nectin-4	Cancer
Sutantatug (SYS6002 Antibody) is a monoclonal antibody targeting Nectin-4, and serves as the antibody moiety of the ADC CRB-701. Sutantatug is applicable to the research of Nectin-4-positive solid tumors, urothelial carcinoma and cervical cancer. The corresponding isotype control for Sutantatug is Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P992337

CS5001 Antibody	ROR	Cancer
CS5001 Antibody is an IgG1 human monoclonal antibody targeting ROR1. CS5001 Antibody can be used for the synthesis of the ADC CS5001. It is applicable to research related to advanced solid tumors and lymphomas. The recommended isotype control is human IgG1 kappa (HY-P99001) .

HY-P992146

Zevontabart MYTX-011 Antibody; Q-397	ADC Antibodies c-Met/HGFR	Cancer
Zevontabart (MYTX-011 Antibody; Q-397) is a pH-dependent anti-c-MET antibody. Zevontabart regulates the trafficking process of c-MET to reduce receptor recycling, and enhances its own endocytosis and accumulation in c-MET-expressing cells. Zevontabart induces cytotoxicity in solid tumor cells and exerts anti-tumor activity in a non-small cell lung cancer xenograft mouse model. Zevontabart can be used to synthesize *ADC, such as: MYTX-011. Zevontabart can be used in studies related to non-small cell lung cancer, with its corresponding isotype control* being Human IgG1 kappa, Isotype Control (HY-P99001) .

Cat. No.	Product Name	Chemical Structure

HY-145149S

Duostatin 5-13C,d3

Duostatin 5- ¹³C,d₃ is the ¹³C-labeled Duostatin 5 (HY-145149). Duostatin 5 is a ADC Cytotoxin designed based on MMAF (HY-15579) and can be used to synthesize ADCs. The preparation of Duostatin 5 has the advantages of fewer synthetic steps, simple operation, less difficulty in quality control, and more stable chemical synthesis process. Duostatin 5 can be linked to the antibody targeting 5T4 (ZV05) by cross-linking with interchain cysteines through a disubstituted C-Lock linker. Duostatin 5 is a click chemistry reagent. It contains an azide group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing alkyne groups. It can also undergo ring strain-driven alkyne-azide cycloaddition (SPAAC) with molecules containing DBCO or BCN groups[1][2].

Cat. No.	Product Name		Classification

HY-145149

Duostatin 5		Azide ADC Synthesis
Duostatin 5 is a ADC Cytotoxin designed based on MMAF (HY-15579) and can be used to synthesize *ADCs. The preparation of Duostatin 5 has the advantages of fewer synthetic steps, simple operation, less difficulty in quality control*, and more stable chemical synthesis process. Duostatin 5 can be linked to the antibody targeting 5T4 (ZV05) by cross-linking with interchain cysteines through a disubstituted C-Lock linker. Duostatin 5 is a click chemistry reagent. It contains an azide group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing alkyne groups. It can also undergo ring strain-driven alkyne-azide cycloaddition (SPAAC) with molecules containing DBCO or BCN groups[1][2].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: